Synthetic Design Lab Unveils Logic-Gated ADC Platform
SAN CARLOS, Calif., April 20, 2026 Synthetic Design Lab announced the first public presentation of its SYNTHBODY™ platform at...
antibody drug conjugate
Advertisement
Eli Lilly to Acquire CrossBridge Bio for ADC Platform
Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...
Boehringer Ingelheim, Zai Lab Advance DLL3 Cancer Trial
Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...
AbbVie Reports Strong Phase 2 Data in Ovarian Cancer
North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...
DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
Advertisements
Zymeworks’ ZW191 Gets FDA Fast Track for Cancer
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
Daiichi Sankyo Expands ENHERTU Use in Japan
TOKYO, JAPAN, March 23, 2026 Daiichi Sankyo has announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...
FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
KEYTRUDA Plus Padcev Extends Survival in MIBC Trial
RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...
Advertisement
